OBJECTIVE: This first pilot study of genome-wide expression as predictor of antidepressant response in late-life depression examined genome-wide transcriptional profiles in a randomized placebo-controlled trial of combined methylphenidate and citalopram. METHODS: Genome-wide transcriptional profiles were examined in peripheral blood leukocytes sampled at baseline and 16 weeks from 35 older adults with major depression, who were randomized to methylphenidate + citalopram, citalopram + placebo, or methylphenidate + placebo. Methylphenidate doses ranged between 10 and 40 mg/day, and citalopram doses ranged between 20 and 60 mg/day. Remission was defined as Hamilton Depression Rating Scale score of 6 or below. Early remission was achieved in the first 4 weeks of treatment. We hypothesized that differential gene expression at baseline can predict antidepressant response. RESULTS: We analyzed gene expression in 24 remitters and 11 non-remitters. At baseline, we found three genes showing higher expression in all remitters versus non-remitters that satisfied the established level of significance: a fold change of 2 and p-value of 0.05 that included HLA-DRB5, SELENBP1, and LOC388588. Two gene transcripts showed higher expression in early remitters at baseline compared with non-remitters. The first gene was CA1 carbonic anhydrase gene, on chromosome 8 involved in respiratory function (fold change 2.54; p = 0.03). The second gene was the SNCA-α-synuclein gene, implicated, which binds to dopamine transporter (fold change 2.1; p = 0.03). CONCLUSIONS: Remission to antidepressants in geriatric depression may be associated with a particular gene expression profile in monoaminergic and metabolic pathways and needs to be replicated in a larger sample.
RCT Entities:
OBJECTIVE: This first pilot study of genome-wide expression as predictor of antidepressant response in late-life depression examined genome-wide transcriptional profiles in a randomized placebo-controlled trial of combined methylphenidate and citalopram. METHODS: Genome-wide transcriptional profiles were examined in peripheral blood leukocytes sampled at baseline and 16 weeks from 35 older adults with major depression, who were randomized to methylphenidate + citalopram, citalopram + placebo, or methylphenidate + placebo. Methylphenidate doses ranged between 10 and 40 mg/day, and citalopram doses ranged between 20 and 60 mg/day. Remission was defined as Hamilton Depression Rating Scale score of 6 or below. Early remission was achieved in the first 4 weeks of treatment. We hypothesized that differential gene expression at baseline can predict antidepressant response. RESULTS: We analyzed gene expression in 24 remitters and 11 non-remitters. At baseline, we found three genes showing higher expression in all remitters versus non-remitters that satisfied the established level of significance: a fold change of 2 and p-value of 0.05 that included HLA-DRB5, SELENBP1, and LOC388588. Two gene transcripts showed higher expression in early remitters at baseline compared with non-remitters. The first gene was CA1 carbonic anhydrase gene, on chromosome 8 involved in respiratory function (fold change 2.54; p = 0.03). The second gene was the SNCA-α-synuclein gene, implicated, which binds to dopamine transporter (fold change 2.1; p = 0.03). CONCLUSIONS: Remission to antidepressants in geriatric depression may be associated with a particular gene expression profile in monoaminergic and metabolic pathways and needs to be replicated in a larger sample.
Authors: George S Alexopoulos; Charles E Glatt; Matthew J Hoptman; Dora Kanellopoulos; Christopher F Murphy; Robert E Kelly; Sarah S Morimoto; Kelvin O Lim; Faith M Gunning Journal: J Affect Disord Date: 2010-03-25 Impact factor: 4.839
Authors: M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds Journal: Psychiatry Res Date: 1992-03 Impact factor: 3.222
Authors: János Kálmán; András Palotás; Anna Juhász; Agnes Rimanóczy; Marietta Hugyecz; Zsuzsa Kovács; Gabriella Galsi; Zoltán Szabó; Magdolna Pákáski; Liliána Z Fehér; Zoltán Janka; László G Puskás Journal: Neurochem Res Date: 2005-11 Impact factor: 3.996
Authors: N D Volkow; R C Gur; G J Wang; J S Fowler; P J Moberg; Y S Ding; R Hitzemann; G Smith; J Logan Journal: Am J Psychiatry Date: 1998-03 Impact factor: 18.112
Authors: Hans-Peter Schneider; Marco D Alt; Michael Klier; Alena Spiess; Fabian T Andes; Abdul Waheed; William S Sly; Holger M Becker; Joachim W Deitmer Journal: Proc Natl Acad Sci U S A Date: 2013-01-07 Impact factor: 11.205
Authors: Ryan Abbott; Donald D Chang; Harris A Eyre; Chad A Bousman; David A Merrill; Helen Lavretsky Journal: Am J Geriatr Psychiatry Date: 2017-05-25 Impact factor: 4.105
Authors: Rafael Leite Dantas; Jana Freff; Oliver Ambrée; Eva C Beins; Andreas J Forstner; Udo Dannlowski; Bernhard T Baune; Stefanie Scheu; Judith Alferink Journal: Cells Date: 2021-04-19 Impact factor: 6.600